Anti hypertensive drugs are expected to get Alzheimer’s disease,The researchers are looking for new therapies to slow the progression of Alzheimer’s disease, and a new study by the American Heart Association has shown that blood pressure nilvadipine does not affect other parts of the brain, . Journal Hypertension.
These results indicate that in some areas the decrease in cerebral blood flow in Alzheimer’s patients can be reversed. An important question, however, is whether the observed increase in cerebral blood flow translates into a clinical benefit.
Alzheimer’s disease is the most common form of dementia. Disease risk increases with age, and the cause is almost unknown. Previous studies have shown that blood flow to the brain decreases in the early stages of Alzheimer’s disease.
Neilbodipine is a calcium channel blocker used in the treatment of hypertension. The researchers looked to see if Alzheimer’s disease patients could help treat Alzheimer’s disease in order to see if Neil-Bodipin and Alzheimer’s disease could help treat Alzheimer’s disease. The researchers randomly assigned 44 participants to receive nilvadipine or placebo for 6 months. Researchers and participants did not know who administered the equally divided drug or placebo between the two groups. At the beginning of the study and six months later, the researchers used unique magnetic resonance imaging (MRI) techniques to measure blood flow to specific areas of the brain.
The results showed that blood flow to the hippocampus (brain memory and learning centers) increased by 20% in the nilvadipine group compared to placebo groups. Blood flow to other parts of the brain did not change in both groups.
“This hypertension treatment does not reduce cerebral blood flow, so it keeps its promise because it can do more harm than good,” said Jurgen Claassen, MD, Ph.D., an associate professor at Radboud University. Medical center in Neimele in the Netherlands. “Even though treatment is not dangerous, hypertension treatment can be important in maintaining brain health in Alzheimer’s patients.”
The researchers note that the sample size is too small and the tracking time is too short to reliably study the effect of this cerebral blood flow increase on structural brain measurements and cognitive measurements.
Study participants were surveyed as part of a large-scale research project that compared nilvadipine and placebo among the 500 mild to moderate mean age 73 years (more than half of the women are white and mostly white) of Alzheimer’s disease between 2013 and 2015 .
The effect on cerebral blood flow was not measured in the large project. Overall, no clinical benefit from the use of nilvadipine was found. However, subgroups of patients with mild symptoms of illness have benefited from the fact that memory is slow.
Previous studies have suggested that hypertension treatment can reduce the risk of developing dementia. The authors believe that a beneficial effect on cerebral blood flow can explain some of this effect.
This study is one of the few studies using this MRI technique to investigate the effect of treatment on cerebral blood flow. Likewise, a minority of similar racial and ethnic groups means that the outcome may not apply to other groups.
“In the future, improvement in blood flow, especially in the hippocampus, can be used as a supportive treatment to slow the progression of Alzheimer’s disease, especially in the early stages of the disease,” Klaasen said.